Skip to main content
Top
Published in: Medical Oncology 3/2007

01-09-2007 | Original Paper

Aberrant expression of Eag1 potassium channels in gastric cancer patients and cell lines

Authors: Xiang-wu Ding, He-sheng Luo, Xiong Jin, Juan-juan Yan, Yao-wei Ai

Published in: Medical Oncology | Issue 3/2007

Login to get access

Abstract

Recently, an interesting relationship between potassium channels and cancer has evolved. The aim of this study is to investigate expression of Eag1 potassium channel in gastric cancer and its role in cancer cells growth.The expression of Eag1 for gasric cancer patients and cell lines as well as gastric adenoma was investigated by immunohistochemistry and reverse transcription polymerase chain reaction. In addition, imipramine was used to identify the involvement of Eag1 in the growth of SGC-7901 and BGC-823 cells. Frequency of positive expression of Eag1 protein was 70.5% (67/95) and Eag1 mRNA was 68.2% (15/22) in gastric cancer primary tissues. Eag1 mRNA was positively expressed in two gastric cell lines. Eag1 protein and mRNA were negatively expressed in paired non-cancerous matched tissues and 5 cases of adenoma tissues. The expression level of Eag1 protein was associated with lymph node metastasis (P = 0.049) and stage (P = 0.039), but had no correlation with sex, age, differentiation grades, and other organs metastases.
Imipramine significantly inhibited the proliferation of SGC-7901 and BGC-823 cells at 12 h and 24 h detected by cells number counting and MTT assay (P < 0.01). The study indicates Eag1 is aberrantly expressed in gastric cancer tissues and cell lines and associated with cancer lymph node metastasis and stage and play an important role in the proliferation of gastric cancer cells.
Literature
2.
go back to reference Warmke JW, Ganetzky B. A family of potassium channel genes related to eag in Drosophila and mammals. Proc. Natl Acad Sci USA 1994;91:3438–3842.PubMedCrossRef Warmke JW, Ganetzky B. A family of potassium channel genes related to eag in Drosophila and mammals. Proc. Natl Acad Sci USA 1994;91:3438–3842.PubMedCrossRef
3.
go back to reference Bauer CK, Schwarz JR. Physiology of EAG KC channels. J Membr Biol 2001;182:1–15.PubMed Bauer CK, Schwarz JR. Physiology of EAG KC channels. J Membr Biol 2001;182:1–15.PubMed
4.
go back to reference Occhiodoro T, Bernheim L, Liu JH, Bijlenga P, Sinnreich M, et al. Cloning of a human ether-a-go–go potassium channel expressed in myoblasts at the onset of fusion. FEBS Lett 1998;434:177–82.PubMedCrossRef Occhiodoro T, Bernheim L, Liu JH, Bijlenga P, Sinnreich M, et al. Cloning of a human ether-a-go–go potassium channel expressed in myoblasts at the onset of fusion. FEBS Lett 1998;434:177–82.PubMedCrossRef
5.
go back to reference Pardo LA, del Camino D, Sanchez A, Alves F, Bruggemann A, et al. Oncogenic potential of EAG K(+) channels. EMBO J 1999;18:5540–7.PubMedCrossRef Pardo LA, del Camino D, Sanchez A, Alves F, Bruggemann A, et al. Oncogenic potential of EAG K(+) channels. EMBO J 1999;18:5540–7.PubMedCrossRef
6.
go back to reference Meyer R, Heinemann SH. Characterization of an eag-like potassium channel in human neuroblastoma cells. J Physiol 1998;508:49–56.PubMed Meyer R, Heinemann SH. Characterization of an eag-like potassium channel in human neuroblastoma cells. J Physiol 1998;508:49–56.PubMed
7.
go back to reference Gavrilova-Ruch O, Schonherr K, Gessner G, Schonherr R, Klapperstuck T, et al. Effects of imipramine on ion channels and proliferation of IGR1 melanoma cells. J Membr Biol 2002;188:137–49.PubMedCrossRef Gavrilova-Ruch O, Schonherr K, Gessner G, Schonherr R, Klapperstuck T, et al. Effects of imipramine on ion channels and proliferation of IGR1 melanoma cells. J Membr Biol 2002;188:137–49.PubMedCrossRef
8.
go back to reference Farias LM, Ocana DB, Diaz L, Larrea F, Avila-Chavez E, et al. Ether a go–go potassium channels as human cervical cancer markers. Cancer Res 2004;64:6996–7001.PubMedCrossRef Farias LM, Ocana DB, Diaz L, Larrea F, Avila-Chavez E, et al. Ether a go–go potassium channels as human cervical cancer markers. Cancer Res 2004;64:6996–7001.PubMedCrossRef
9.
go back to reference Mello de Queiroz F, Suarez-Kurtz G, Stuhmer W, Pardo LA. Ether a go–go potassium channel expression in soft tissue sarcoma patients. Mol Cancer 2006;5:42.CrossRef Mello de Queiroz F, Suarez-Kurtz G, Stuhmer W, Pardo LA. Ether a go–go potassium channel expression in soft tissue sarcoma patients. Mol Cancer 2006;5:42.CrossRef
10.
go back to reference Weber C, Mello de Queiroz F, Downie BR, Suckow A, Stuhmer W, et al. Silencing the activity and proliferative properties of the human EagI potassium channel by RNA interference. J Biol Chem 2006;281: 13030–7. Erratum in: J Biol Chem 2006; 281:17540. Weber C, Mello de Queiroz F, Downie BR, Suckow A, Stuhmer W, et al. Silencing the activity and proliferative properties of the human EagI potassium channel by RNA interference. J Biol Chem 2006;281: 13030–7. Erratum in: J Biol Chem 2006; 281:17540.
11.
go back to reference Ouadid-Ahidouch H, Le Bourhis X, Roudbaraki M, Toillon RA, Delcourt P, et al. Changes in the K+ current-density of MCF-7 cells during progression through the cell cycle: possible involvement of a h-ether a-gogo K+ channel. Recept Channels 2001;7:345–56.PubMed Ouadid-Ahidouch H, Le Bourhis X, Roudbaraki M, Toillon RA, Delcourt P, et al. Changes in the K+ current-density of MCF-7 cells during progression through the cell cycle: possible involvement of a h-ether a-gogo K+ channel. Recept Channels 2001;7:345–56.PubMed
12.
go back to reference Schonherr R. Clinical relevance of ion channels for diagnosis and therapy of cancer. J Membr Biol 2005;205:175–84.PubMedCrossRef Schonherr R. Clinical relevance of ion channels for diagnosis and therapy of cancer. J Membr Biol 2005;205:175–84.PubMedCrossRef
13.
go back to reference Pardo LA, Contreras-Jurado C, Zientkowska M, et al. Role of voltage gated potassium channels in cancer. J Membr Biol 2005;205:115–24.PubMedCrossRef Pardo LA, Contreras-Jurado C, Zientkowska M, et al. Role of voltage gated potassium channels in cancer. J Membr Biol 2005;205:115–24.PubMedCrossRef
15.
go back to reference Stuhmer W, Alves F, Hartung F, et al. Potassium channels as tumour markers. FEBS Lett 2006;580:2850–2.PubMedCrossRef Stuhmer W, Alves F, Hartung F, et al. Potassium channels as tumour markers. FEBS Lett 2006;580:2850–2.PubMedCrossRef
16.
go back to reference Gutman GA, Chandy KG, Grissmer S, et al. International Union of Pharmacology. LIII. Nomenclature and molecular relationships of voltage-gated potassium channels. Pharmacol Rev 2005;57:473–508.PubMedCrossRef Gutman GA, Chandy KG, Grissmer S, et al. International Union of Pharmacology. LIII. Nomenclature and molecular relationships of voltage-gated potassium channels. Pharmacol Rev 2005;57:473–508.PubMedCrossRef
17.
go back to reference Garcia-Ferreiro RE, Kerschensteiner D, Major F, Monje F, Stuhmer W, Pardo LA. Mechanism of block of hEag1 K+ channels by imipramine and astemizole. J Gen Physiol 2004;124:301–17.PubMedCrossRef Garcia-Ferreiro RE, Kerschensteiner D, Major F, Monje F, Stuhmer W, Pardo LA. Mechanism of block of hEag1 K+ channels by imipramine and astemizole. J Gen Physiol 2004;124:301–17.PubMedCrossRef
Metadata
Title
Aberrant expression of Eag1 potassium channels in gastric cancer patients and cell lines
Authors
Xiang-wu Ding
He-sheng Luo
Xiong Jin
Juan-juan Yan
Yao-wei Ai
Publication date
01-09-2007
Publisher
Humana Press Inc
Published in
Medical Oncology / Issue 3/2007
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-007-0015-y

Other articles of this Issue 3/2007

Medical Oncology 3/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine